Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs Propofol for EUS-FNA/FNB Sedation
NCT05437497Unknown
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Aug 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of remimazolam (2 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoint: Cardiopulmonary adverse event incidence. Status: unknown.
02
Drugs
remimazolam
Beyond the preview
Go deeper on NCT05437497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05437497.